The mayor said he plans to run as a team with three current Town Council members this November, seeking his fifth term.

-Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

Sanofi‘s participation at the JP Morgan Healthcare Conference on January 14, 2025, was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future. The CEO ...

Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for t ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank of America Securities reiterated a Buy rating on the ...

In 2014, Lilly inked a licensing agreement with Sanofi that allows the latter company to pursue regulatory approval of OTC Cialis in the U.S., Europe, Canada and Australia.

Welcome to the Sanofi Presentation at the 43rd J.P. Morgan Healthcare Conference. I'm Richard Vosser, European Pharma Analyst at J.P. Morgan, and it's my great pleasure to welcome not just the CEO ...